Full Year Results

FY26

August 2026

Advanced Manufacturing for Breakthrough Medicines

Disclaimer and Important Notices

This presentation has been prepared by IDT Australia Limited ACN 006 522 970 (Company). It contains general background information only which is current at the date of this presentation unless otherwise specified. It contains selected summary information and does not purport to be all-inclusive, comprehensive or to contain all of the information that may be relevant, or which a prospective investor may require in evaluating a possible investment in the Company. Prospective investors should not rely on the information contained in this presentation and must satisfy themselves as to the accuracy of all such information. This presentation has been prepared based on information available at the time of preparation and is subject to change without notice.

This presentation is provided for general information purposes only. It does not constitute an offer, invitation, solicitation, or recommendation with respect to the purchase or sale of securities in the Company in any jurisdiction. It is not a prospectus, product disclosure statement, pathfinder document, or any other type of public offer disclosure document for the purposes of the Corporations Act 2001 (Cth) and has not been, and is not required to be, lodged with the Australian Securities and Investments Commission.

This presentation does not constitute investment or financial product advice. It is not intended to be used as the basis for making a financial decision, nor to constitute legal, tax, accounting, or other advice, and has been prepared without taking account of any person's individual investment objectives, financial situation or particular needs. Before making an investment decision, the recipient should consider their own situation and conduct their own independent investigation and assessment of the contents of this presentation. Past performance is not an indication of future performance.

This presentation may contain forward-looking statements, guidance, forecasts, estimates, prospects, projections, or statements in relation to future matters that may involve risks or uncertainties and significant items of subjective judgement and assumptions of future events that may or may not eventuate (Forward Statements). Forward Statements can generally be identified by the use of words such as "anticipate", "estimates", "will", "should", "could", "may", "expects", "plans", "forecast", "target" or similar expressions. They are provided as a general guide only and should not be relied upon as an indication or guarantee of future performance. No independent third party has reviewed the reasonableness of any such statements or assumptions.

An investment in the Company's securities is subject to known and unknown risks, many of which are beyond the control of the Company, including factors and risks specific to the industry as well as general economic conditions, prevailing exchange rates and interest rates and conditions in the financial markets. Prospective investors should make their own enquiries and investigations regarding all information in this presentation, including the assumptions, uncertainties and contingencies which may affect the future operations of the Company.

All dollar values are in Australian dollars ($ or A$) unless otherwise stated. To the maximum extent permitted by law, the Company, its Directors and officers exclude and disclaim all liability for any expenses, losses, damages or costs incurred as a result of the information in this presentation being inaccurate or incomplete, and make no representation or warranty, express or implied, as to the currency, accuracy, reliability or completeness of information in this presentation.

FY26 RESULTS AT A GLANCE

Turning Point

FY26 EBITDA	REVENUE, 3 VERTICALS	TOTAL REVENUE (inc disb)	AVAILABLE FUNDS
–$0.9M	$16.8M	$20.4M	$9.7M
▲ 85% YoY FY25: –$6.3M	▲ 16.5% YoY FY25: $14.4M	▲ vs FY25 FY25: $19.2M	to Fund Growth

Strategic Reset Objectives

Focus on high-value repeat clients, prioritise profit over revenue growth and strengthen financial discipline.

Three Verticals

API Manufacturing	$5.4M	▲ 29.4%
Solid Oral	$5.5M	▲ 51.7%
Sterile (Adv. Therapies)	$5.9M	▼ 10.8%

The Turnaround

EBITDA loss narrowed by 85%



KEY MESSAGES & OUTLOOK

Positive EBITDA
Forecast for FY27

$50M Revenue
FY29 Target

$7M Capex
New Sterile Line + Oral upgrade

Award Winner
Asia-Pacific
RNA Excellence Awards 2026

Sanofi
“Preferred Vendor”

Verticals — Business Performance

Core growth platforms

Active Pharmaceutical Ingredient (API)

Revenue up 29% to $5.4M

- Small-molecule, complex high-potency chemistry
- Foundation business and platform for growth
- Flow-on work to the other two verticals

Developing the key ingredient

Solid Oral Manufacturing

Revenue up 52% to $5.5M

- Capitalising on radiopharmaceutical opportunities
- Servicing medicinal cannabis & psychedelic clients
- Tablets, capsules and liquids at scale

Finished drug — tablets & capsules

Sterile Manufacturing

Revenue down 11% to $5.9M

- Movement reflects timing of contracts
- Key growth driver for the group
- mRNA demand + Sanofi “Preferred Vendor” status

Finished drug — injectables

◇ *Figures shown as placeholders — to be confirmed*

Operational Momentum

Strong Near and Medium-Term Outlook

NEAR- & MEDIUM-TERM DRIVERS

1

Repeat & follow-on work

with existing strategic clients in Australia, the US, EU and APAC

2

Expand capabilities

to position IDT as one of the few CDMOs in select high-value markets

3

Deepen IDT's competitiveness

to back new customer-acquisition initiatives in high-growth biotech clusters

4

Increase market visibility

via targeted conferences & in-market engagement

FY27

- Double Digit Revenue Growth
- Forecasting Positive EBITDA

FY29

- $50M Revenue Target
- Strong EBITDA Margins

Global Market Overview

Growth Across all Three Verticals

TAM - US$130B+

IDT is a specialist, agile CDMO focused on complex Small-Molecule API, and Sterile & Non-Sterile manufacturing — delivering the agility and responsiveness required by emerging biotech and pharmaceutical companies.

Small Molecule API

TAM	US$232B
SAM	**US$47B**
CAGR	**7.30%**

Solid Oral

TAM	US$636B
SAM	**US$46B**
CAGR	**6.56%**

Sterile Injectables (incl. biologics)

TAM	US$659B
SAM	**US$38B**
CAGR	**11.20%**

Three regions, one market **US · EU · APAC** — Total SAM US$130B. The US is the largest opportunity today; Europe & APAC offer significant expansion potential.

Market sizing sourced from third-party research — see references in the appendix.

Pathway to $50M Revenue

FY29 Revenue Target



>$50M by FY29

0.027% of Addressable Market

01

Strategic positioning

Specialist in complex small-molecule API and sterile & non-sterile manufacturing — an agile solution for emerging biotech and pharma.

02

Existing customer expansion

Maximise value from strategic accounts — expanding scope, advancing programs from clinical to commercial and securing long-term partnerships.

03

Strategic account management

Build deep, long-term partnerships through proactive account planning.

04

Market growth & lead generation

Grow visibility and build the IDT brand to generate a strong, qualified pipeline through targeted channels and events.

05

New customer acquisition

Win new clients across the US, Europe & APAC by converting the pipeline into long-term partnerships.

High-Tech Capability Expansion

$7M Business Investment

New Sterile Manufacturing Line

Isolator Technology — the global gold standard for Grade A aseptic fill-finish

- Enables commercial-scale fill-finish
- Fully vertically integrated finished-dose service
- Serves ADCs, Biologics, Biosimilars, mRNA Vaccines & Specialty Injectables
- Strong pricing power given the shortage of qualified CDMOs in these segments



Solid oral dose upgrade

Tablet Press, Coating, Solids Handling & Complete Bottle Line

- Increases manufacturing throughput
- Strengthens Tablet Press, Coating & Bottle-Line capabilities
- Access to a wider range of Oral Solid-Dose contracts — including complex modified-release and fixed-dose combinations

$7M Capital Investment (FY27-FY28)

Fully Funded (Existing Debt Facility)

Access to Government Grant Programs

Supports Australia's Sovereign Capabilities

Outlook and Highlights

The confident path forward

Profit Recovery

- Improved operating leverage — EBITDA improvement 85% on 16.5% revenue growth in FY26
- FY26 cost savings - ~$2.5m
- Tangible growth results from the strategic reset
- Solid performance & outlook across all three verticals

FY27 Outlook

- Double digit revenue growth
- Positive EBITDA forecast for the year
- Strong pipeline & leverage to growing global demand for new-generation drugs
- Improved potential for repeat / follow-on work via end-to-end services

$50M Target Annualised Revenue - FY29

- Expanding local & international strategic accounts
- Tapping high-value global segments poorly served by competitors
- Backed by a fully funded $7M investment program and market tailwinds

Competitive Edge

- World-class facilities and market-leading position
- Strong balance sheet with $9.7M in available funds
- One of few regional CDMOs with sterile fill + full end-to-end services

Board of Directors

Experienced board and leadership team

Mark Simari

Executive Chair/CEO

An experienced and accomplished professional in the health industry with over 17 years' board experience across a diverse range of organisations. Former managing director and co-founder of Paragon Care (2008–2018), which he helped build into one of the largest independent healthcare suppliers in Australia and New Zealand — spanning capital equipment, consumables, devices, and service and maintenance.

Geoffrey Sam, OAM

Non-Executive Director

Brings a wealth of healthcare experience and accomplishments. Currently Chairperson and Independent Non-Executive Director at Earlypay Ltd (ASX:EPY); Co-founder and board member of Healthe Care Australia Pty Ltd, a privately owned healthcare company comprising a portfolio of 14 hospitals.

Dr Jane Ryan

Non-Executive Director

Over 30 years of international experience in the pharmaceutical and biotechnology industries, with executive roles across R&D management, business development and alliance management. Has led many successful fundraising campaigns and licensing initiatives, including the winning of a US$230 million US Government contract. Also, on the boards of Neuphoria Therapeutics Inc. (NASDAQ:NEUP) and a viral vector manufacturing facility.

Investor & Media Enquiries

Brendon Lau
brendon@vantagepointpartners.com.au
+61 409 341 613

Advanced Manufacturing for Breakthrough Medicines

Appendix

REFERENCES & DEFINITIONS

REFERENCES

1 **Mordor Intelligence — Active Pharmaceutical Ingredients (API) market**
mordorintelligence.com/industry-reports/global-active-pharmaceutical-ingredients-api-market

2 **Mordor Intelligence — Oral Solid Dosage formulation market**
mordorintelligence.com/industry-reports/oral-solid-dosage-pharmaceutical-formulation-market

3 **Mordor Intelligence — Sterile Injectable Drugs market**
mordorintelligence.com/industry-reports/sterile-injectable-drugs-market

4 **Grand View Research — Small Molecule API CDMO market**
grandviewresearch.com/industry-analysis/small-molecule-api-cdmo-market-report

5 **Straits Research — Oral Solid Dosage CDMO market**
straitsresearch.com/press-release/oral-solid-dosage-cdmo-market-size

6 **Grand View Research — Sterile Injectables CDMO market**
grandviewresearch.com/industry-analysis/sterile-injectables-cdmo-market-report

DEFINITIONS

TAM — **Total Addressable Market**
Total market demand — the maximum revenue opportunity if 100% market share were captured.

SAM — **Serviceable Addressable Market**
The share of the TAM that IDT's capabilities, capacity and geographic reach can realistically serve.

CAGR — **Compound Annual Growth Rate**
The annualised, compounded rate at which a market grows over a defined period.

CDMO — **Contract Development & Manufacturing Organisation**
An outsourced partner providing drug development and manufacturing services to pharma and biotech companies.